Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 8, 2009 - Issue 4
Submit an article Journal homepage
213
Views
31
CrossRef citations to date
0
Altmetric
Reviews

Type I IFNs and their role in the development of autoimmune diseases

Laura M Burdick Dermatology & Plastic Surgery Institute, Cleveland Clinic Health System, Department of Dermatology, 9500 Euclid Avenue, Desk A61 Cleveland, Ohio 44195, USA
, MD,
Najwa Somani Dermatology & Plastic Surgery Institute, Cleveland Clinic Health System, Department of Dermatology, 9500 Euclid Avenue, Desk A61 Cleveland, Ohio 44195, USA; Dermatology & Plastic Surgery Institute, Cleveland Clinic Health System Department of Dermatopathology, 9500 Euclid Avenue, Desk A61 Cleveland, Ohio 44195, USA
, MD FRCPC &
Ally-Khan Somani Dermatology & Plastic Surgery Institute, Cleveland Clinic Health System, Department of Dermatology, 9500 Euclid Avenue, Desk A61 Cleveland, Ohio 44195, USA; Dermatology & Plastic Surgery Institute, Cleveland Clinic Health System, Dermatologic Surgery and Cutaneous Oncology, 9500 Euclid Ave, Desk A61 Cleveland, OH 44195, USA +216 444 5489; + 216 636 0863; [email protected]
, MD PhD
Pages 459-472 | Published online: 24 Jun 2009

Bibliography

  • Alazemi S, Campos MA. Interferon-induced sarcoidosis. Int J Clin Pract 2006;60:201-11
  • Houglum JE. Interferon: mechanisms of action and clinical value. Clin Pharm 1983;2:20-8
  • Baccala R, Hoebe K, Kono DH, et al. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13:543-51
  • Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997;112:1017-21
  • Baechler EC, Batliwalla FM, Reed AM, et al. Gene expression profiling in human autoimmunity. Immunol Rev 2006;210:120-37
  • Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78
  • Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307-36
  • Wenzel J, Scheler M, Bieber T, Tuting T. Evidence for a role of type I interferons in the pathogenesis of dermatomyositis. Br J Dermatol 2005;153:462-3
  • Crow MK, Wohlgemuth J. Microarray analysis of gene expression in lupus. Arthritis Res Ther 2003;5:279-87
  • Baccala R, Kono DH, Theofilopoulos AN. Interferons as pathogenic effectors in autoimmunity. Immunol Rev 2005;204:9-26
  • Tezak Z, Hoffman EP, Lutz JL, et al. Gene expression profiling in DQA1*0501+children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002;168:4154-63
  • Fiorentino DF. Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease. Arch Dermatol 2008;144:1379-82
  • Borden EC, Sen GC, Uze G, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90
  • Marzouk K, Saleh S, Kannass M, Sharma OP. Interferon-induced granulomatous lung disease. Curr Opin Pulm Med 2004;10:435-40
  • Levesque MC, Ward FE, Jeffery DR, Weinberg JB. Interferon-beta1A-induced polyarthritis in a patient with the HLA-DRB1*0404 allele.[see comment]. Arthritis Rheum 1999;42:569-73
  • Schellekens H, de Reus A, vd Meide PH. The chimpanzee as a model to test the side effects of human interferons. J Med Primatol 1984;13:235-45
  • Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006;8:907-22
  • Heathcote EJ. Autoimmune hepatitis and chronic hepatitis C: latent or initiated by interferon therapy?[comment]. Gastroenterology 1995;108:1942-4
  • Taniguchi T, Takaoka A. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 2002;14:111-6
  • Uddin S, Platanias LC. Mechanisms of type-I interferon signal transduction. J Biochem Mol Biol 2004;37:635-41
  • Haas AL, Ahrens P, Bright PM, Ankel H. Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J Biol Chem 1987;262:11315-23
  • Ritchie KJ, Zhang DE. ISG15: the immunological kin of ubiquitin. Semin Cell Dev Biol 2004;15:237-46
  • Zhao C, Denison C, Huibregtse JM, et al. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA 2005;102:10200-5
  • Malakhov MP, Kim KI, Malakhova OA, et al. High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction. J Biol Chem 2003;278:16608-13
  • Malakhova OA, Yan M, Malakhov MP, et al. Protein ISGylation modulates the JAK-STAT signaling pathway 135. Genes Dev 2003;17:455-60
  • D'Cunha J, Knight E Jr, Haas AL, et al. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 1996;93:211-5
  • Blomstrom DC, Fahey D, Kutny R, et al. Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. J Biol Chem 1986;261:8811-6
  • Haller O, Kochs G. Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic 2002;3:710-7
  • Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem 1995;43:47-52
  • David M, Chen HE, Goelz S, et al. Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 1995;15:7050-8
  • O'Shea JJ, Watford W. A peek at PIAS. Nat Immunol 2004;5:875-6
  • Kumar KG, Krolewski JJ, Fuchs SY. Phosphorylation and specific ubiquitin acceptor sites are required for ubiquitination and degradation of the IFNAR1 subunit of type I interferon receptor. J Biol Chem 2004;279:46614-20
  • Hida S, Ogasawara K, Sato K, et al. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 2000;13:643-55
  • Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003;197:777-88
  • Kono DH, Baccala R, Theofilopoulos AN. Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 2003;36:503-10
  • Arakura F, Hida S, Ichikawa E, et al. Genetic control directed toward spontaneous IFN-alpha/IFN-beta responses and downstream IFN-gamma expression influences the pathogenesis of a murine psoriasis-like skin disease. J Immunol 2007;179:3249-57
  • Akahoshi M, Nakashima H, Shirakawa T. Roles of genetic variations in signalling/immunoregulatory molecules in susceptibility to systemic lupus erythematosus. Semin Immunol 2006;18:224-9
  • Kozyrev SV, Arcon-Riquelme ME. The genetics and biology of Irf5-mediated signaling in lupus. Autoimmunity 2007;40:591-601
  • Scott GM. Interferon: pharmacokinetics and toxicity. Philos Trans R Soc Lond B Biol Sci 1982;299:91-107
  • Veronese FM, Mero A. The impact of PEGylation on biological therapies. BioDrugs 2008;22:315-29
  • Munafo A, Trinchard-Lugan I, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998;5:187-93
  • Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007;68:S8-11
  • Somani AK, Swick AR, Cooper KD, Mccormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008;144:1341-9
  • Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59-68
  • Gota C, Calabrese L. Induction of clinical autoimmune disease by therapeutic interferon-alpha. Autoimmunity 2003;36:511-8
  • Roy V, Newland AC. Raynaud's phenomenon and cryoglobulinaemia associated with the use of recombinant human alpha-interferon. Lancet 1988;1:944-5
  • Ashrafi GH, Brown DR, Fife KH, Campo MS. Down-regulation of MHC class I is a property common to papillomavirus E5 proteins. Virus Res 2006;120:208-11
  • Zou Y, Bresnahan W, Taylor RT, Stastny P. Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 2005;174:3098-104
  • Gregory DJ, Olivier M. Subversion of host cell signalling by the protozoan parasite Leishmania. Parasitology 2005;130 (Suppl):S27-35
  • Biron CA. Interferons alpha and beta as immune regulators–a new look. Immunity 2001;14:661-4
  • Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med 2000;192:219-26
  • Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994;10:115-50
  • De SP, Edy VG, Billiau A. Interferon-induced skin reactivity in man. Lancet 1977;2:47-8
  • Oppenheim Y, Ban Y, Tomer Y. Interferon induced Autoimmune Thyroid Disease (AITD): a model for human autoimmunity. Autoimmun Rev 2004;3:388-93
  • Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-alpha treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990;227:207-10
  • Durelli L, Ferrero B, Oggero A, et al. Thyroid function and autoimmunity during interferon beta-1b treatment: a multicenter prospective study. J Clin Endocrinol Metab 2001;86:3525-32
  • Crispin JC, Az-Jouanen E. Systemic lupus erythematosus induced by therapy with interferon-beta in a patient with multiple sclerosis. Lupus 2005;14:495-6
  • Fattovich G, Giustina G, Favarato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol 1996;24:38-47
  • Fentiman IS, Balkwill FR, Thomas BS, et al. An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer. Eur J Cancer Clin Oncol 1988;24:1299-303
  • Caraccio N, Dardano A, Manfredonia F, et al. Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. J Clin Endocrinol Metab 2005;90:4133-7
  • Farkas L, Beiske K, Lund-Johansen F, et al. Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001;159:237-43
  • Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases 22. J Invest Dermatol 2002;119:1096-102
  • Schoenemeyer A, Barnes BJ, Mancl M, et al. The Interferon Regulatory Factor, IRF5, Is a Central Mediator of Toll-like Receptor 7 Signaling. J Biol Chem 2005;280:17005-12
  • Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998;352:1825-6
  • Dietrich LL, Bridges AJ, Albertini MR. Dermatomyositis after interferon alpha treatment. Med Oncol 2000;17:64-9
  • Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001;1:147-53
  • Walsh RJ, Kong SW, Yao Y, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92
  • Wenzel J, Schmidt R, Proelss J, et al. Type I interferon-associated skin recruitment of CXCR3+ lymphocytes in dermatomyositis. Clin Exp Dermatol 2006;31:576-82
  • Shiozawa S, Shiozawa K, Kita M, et al. A preliminary study on the effect of alpha-interferon treatment on the joint inflammation and serum calcium in rheumatoid arthritis. Br J Rheumatol 1992;31:405-8
  • Alsalameh S, Manger B, Kern P, Kalden J. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson. Arthritis Rheum 1998;41:754
  • Han SW, Lee WK, Kwon KT, et al. Association of polymorphisms in interferon regulatory factor 5 gene with rheumatoid arthritis: a metaanalysis. J Rheumatol 2009;36:693-7
  • Sigurdsson S, Padyukov L, Kurreeman FA, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007;56:2202-10
  • Altintas A, Alici Y, Melikoglu M, Siva A. Arthritis during interferon beta-1b treatment in multiple sclerosis. Mult Scler 2002;8:534-6
  • Somani AK, Yang MF, Cooper KD, Mccormick TS. Cytokines and Psoriasis - When cytokine become “pathokines”. G Ital Dermatol E Venereol 2007;142:679-90
  • Tonel G, Conrad C. Interplay between keratinocytes and immune cells-recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol 2009;41:963-8
  • Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43
  • Yao Y, Richman L, Morehouse C, et al. Type I interferon: potential therapeutic target for psoriasis? PLoS ONE 2008;3:e2737
  • Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol 1991;125:463-5
  • Gilliet M, Conrad C, Geiges M, et al. Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 2004;140:1490-5
  • Fanti PA, Dika E, Vaccari S, et al. Generalized psoriasis induced by topical treatment of actinic keratosis with imiquimod. Int J Dermatol 2006;45:1464-5
  • Rajan N, Langtry JA. Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas. Clin Exp Dermatol 2006;31:140-1
  • Wu JK, Siller G, Strutton G. Psoriasis induced by topical imiquimod. Australas J Dermatol 2004;45:47-50
  • Palucka AK, Blanck JP, Bennett L, et al. Cross-regulation of TNF and IFN-alpha in autoimmune diseases. Proc Natl Acad Sci USA 2005;102:3372-7
  • de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions.[see comment]. Arch Dermatol 2007;143:223-31
  • Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? J Clin Rheumatol 2008;14:353-6
  • Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002;97:767-8
  • Fabris P, Floreani A, Tositti G, et al. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-58
  • Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44:658-64
  • Eibl N, Gschwantler M, Ferenci P, et al. Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-alpha. Eur J Gastroenterol Hepatol 2001;13:295-8
  • Wong FS, Wen L. IFN-alpha can both protect against and promote the development of type 1 diabetes. Ann NY Acad Sci 2008;1150:187-9
  • Szodoray P, Szollosi Z, Gyimesi E, et al. Sarcoidosis in patients with mixed connective tissue disease: clinical, genetic, serological and histological observations. Rheumatol Int 2008;28:743-7
  • Bobbio-Pallavicini E, Valsecchi C, Tacconi F, et al. Sarcoidosis following beta-interferon therapy for multiple myeloma. Sarcoidosis 1995;12:140-2
  • Rubinowitz AN, Naidich DP, Alinsonorin C. Interferon-induced sarcoidosis. J Comput Assist Tomogr 2003;27:279-83
  • Wandl UB, Kloke O, Nagel-Hiemke M, et al. Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemia. Br J Haematol 1992;81:516-9
  • Abdi EA, Brien W, Venner PM. Auto-immune thrombocytopenia related to interferon therapy. Scand J Haematol 1986;36:515-9
  • Brinkmann V, Geiger T, Alkan S, Heusser CH. Interferon alpha increases the frequency of interferon gamma-producing human CD4+T cells. J Exp Med 1993;178:1655-63
  • Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008;20:538-44
  • Lleo A, Selmi C, Invernizzi P, et al. The consequences of apoptosis in autoimmunity. J Autoimmun 2008;31:257-62
  • Mackay IR, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. J Autoimmun 2008;30:5-11
  • Castiblanco J, Anaya JM. The nature and nurture of common autoimmunity. Ann NY Acad Sci 2007;1109:1-8
  • Bankovich AJ, Girvin AT, Moesta AK, Garcia KC. Peptide register shifting within the MHC groove: theory becomes reality. Mol Immunol 2004;40:1033-9
  • Gregersen PK. HLA class II polymorphism: implications for genetic susceptibility to autoimmune disease. Lab Invest 1989;61:5-19
  • Rajagopalan S, Long EO. Understanding how combinations of HLA and KIR genes influence disease. J Exp Med 2005;201:1025-9
  • Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306
  • Grob JJ, Suzini F, Richard MA, et al. Large keratoacanthomas treated with intralesional interferon alfa-2a. J Am Acad Dermatol 1993;29:237-41
  • Oberg K, Norheim I, Lind E, et al. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results. Cancer Treat Rep 1986;70:1297-304
  • Costanzi JJ, Pollard RB. The use of interferon in the treatment of multiple myeloma. Semin Oncol 1987;14:24-8
  • Fujimura T, Okuyama R, Watabe A, et al. Interferon-alpha is effective for CD4(+), CCR4(-) mycosis fungoides. Int J Dermatol 2007;46:435-8
  • Zinzani PL, Mazza P, Gherlinzoni F. Beta interferon in the treatment of mycosis fungoides. Haematologica 1988;73:547-8
  • Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527-30
  • Goksugur N, Karabay O. Eyelash and eyebrow trichomegaly induced by interferon-alfa 2a. Clin Exp Dermatol 2007;32:583-4
  • Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995;13:2401-7
  • Lee SW, Kim KC, Oh DH, et al. A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B. J Korean Med Sci 2002;17:141-3
  • Ladoyanni E, Nambi R. Psoriasis exacerbated by interferon-alpha in a patient with chronic myeloid leukemia. J Drugs Dermatol 2005;4:221-2
  • Schmutz J, Barbaud A, Trechot P. [Subacute cutaneous lupus erythematosus and interferon beta-1 a]. Ann Dermatol Venereol 2000;127:237
  • Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-alpha therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005;24:178-81
  • Goyal HK, Wadhwa J, Arora B, et al. Interferon-induced lupus nephritis in a patient with chronic myeloid leukemia. Leuk Lymphoma 2005;46:481-2
  • Linden D. Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet 1998;352:878-9
  • Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996;193:65-6
  • Sidhu-Malik NK, Kaplan AL. Multiple fixed drug eruption with interferon/ribavirin combination therapy for hepatitis C virus infection. J Drugs Dermatol 2003;2:570-3
  • Kirsner RS, Anhalt GJ, Kerdel FA. Treatment with alpha interferon associated with the development of paraneoplastic pemphigus. Br J Dermatol 1995;132:474-8
  • Niizeki H, Inamoto N, Nakamura K, et al. A case of pemphigus foliaceus after interferon alpha-2a therapy. Dermatology 1994;189(Suppl 1):129-30
  • Parodi A, Semino M, Gallo R, Rebora A. Bullous eruption with circulating pemphigus-like antibodies following interferon-alpha therapy. Dermatology 1993;186:155-7
  • D'Hondt L, Delannoy A, Docquier C. Hypothyroidism and arthritis during interferon therapy. Clin Rheumatol 1993;12:415-7
  • Mangan KF, Zidar B, Shadduck RK, et al. Interferon-induced aplasia: evidence for T-cell-mediated suppression of hematopoiesis and recovery after treatment with horse antihuman thymocyte globulin. Am J Hematol 1985;19:401-13
  • Tappero G, Guerrasio A, Gallo M, et al. Interferon-induced “lupoid” thrombocytopenia in chronic hepatitis C. J Hepatol 1996;24:124
  • Weitz IC. Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab. Am J Hematol 2005;78:138-41
  • Arimura K, Arima N, Ohtsubo H, et al. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta Haematol 2004;112:217-8
  • Wasmuth HE, Stolte C, Geier A, et al. The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C. BMC Infect Dis 2004;4:4

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.